Founded in 1993, Zhuhai United Laboratories Co., Ltd. completed its manufacturing facility in 1998 and was one of the first pharmaceutical companies to establish operations in the Sanzao Technology Park of Jinwan District. At present, it has established production bases in both Sanzao and Nanshui towns within Jinwan District, Zhuhai, covering a total area of 450,000 square meters and employing approx. 2800 people, primarily focused on the production and R&D of APIs and finished products. The products include insulin, penicillin, cephalosporin, clavulanate, and penem in more than 50 varieties. At present, the oral semi-synthetic penicillin workshop has an annual production capacity exceeding 5,000 tons. The annual production capacity of cephalosporin and clavulanate with brand names Gold Clavate and Silver Clavate reaches about 1,000 tons. With a large insulin production facility, the company is the only enterprise in China that utilizes genetic engineering expression technology of Pichia pastoris to produce insulin products, and it is also the first domestic enterprise that produces both second-generation and third-generation insulin.

The company has a chemical drug research platform with approx. 100 R&D personnel. Currently, there are over 10 products under development, covering areas such as antibiotics, immunity inhibitor, ophthalmic and dermatological medications. For the new products, applications have been filed for patents for invention. As of February 2024, 15 applications for patents for invention have been authorized; in addition, a number of applications for patents are in the announcement state. In the future, the chemical drug research platform will continue to strengthen collaboration with other research institutions in industry-academia-research partnerships. Through forward-looking new drug R&D efforts, the company aims to develop and reserve new drug varieties.